Showing 2901-2910 of 6036 results for "".
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Painhttps://modernod.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. “With
- Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in UShttps://modernod.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States. Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractiv
- SIFI Launches Dry Eye Disease Device Synfohttps://modernod.com/news/sifi-launches-dry-eye-disease-synfo/2478726/SIFI announced the launch of Synfo, a novel medical device for dry eye disease. The new hypotonic formulation is a synergistic blend of two polymers—sodium hyaluronate and xanthan gum—and two osmoprotectants, betaine and glycine. In addition to moisturizing and lubricating, Synfo is design
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/Ocular Therapeutix announced the submission of the supplemental new drug application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-primary-endpoints-met-in-phase-2-trial-of-investigational-treatment-for-contact-lens-discomfort/2478686/Azura Ophthalmics announced topline results from a phase 2 clinical trial evaluating the company’s investigational therapy for the treatment of contact lens discomfort (CLD). The ECLIPTIC study examining Azura’s lead asset, AZR-MD-001, met its primary endpoints by showing statistically significan
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Demand, Pay for Travel ICU Nurses Soar as Hospitals Face Staff Crunch Due to COVID-19https://modernod.com/news/demand-pay-for-travel-icu-nurses-soar-as-hospitals-face-staff-crunch-due-to-covid-19/2478681/Staffing crunches caused by COVID-19 created a massive 305% increase in demand for intensive care unit travel nurses from March to November, according to a new report, as
- AAO: Leading Advocates for Seniors’ Timely Access to Care Legislation Applaud Senate Bill Introductionhttps://modernod.com/news/aao-leading-advocates-for-seniors-timely-access-to-care-legislation-applaud-senate-bill-introduction/2478675/The Regulatory Relief Coalition (RRC), a group of national physician specialty organizations, announced its strong support for the Improving Seniors’ Timely Access to Care Act, legislation introduced today in the U.S. Senate by Senators Sherrod Brown (D-OH) and John Thune (R-SD). The